



REINSURANCE **HOT NEWS**

October 14, 2022

New High Cost Specialty Drugs (BIO) Reinsured

- The following drugs have been approved for catastrophic High Cost Specialty Drug (BIO) reinsurance effective 10/01/2022:
 - Haegarda – Treats Hereditary Angiodema(HAE)
 - Kalbitor – Treats sudden attacks of Hereditary Angiodema (HAE)
 - Icatibant – Also treats sudden attacks of Hereditary Angiodema (HAE)
 - Orladeyo – Also treats attacks of HAE
 - Takzyro – Also treats HAE
 - Kanuma – Treats Lysosomal Acid Lipase Deficiency (LAL-D)
 - Galafold – Treats Fabry disease and an amenable GLA gene variant
 - Ultomiris- Treats Myasthenia Gravis
 - Firdapse- Treats Lambert-Eaton myasthenic syndrome(LEMS)

